MedTrace Logo

A QT/QTc Evaluation Study of TS-172 in Healthy Adult Subjects

NCT06837155 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2025-06-06

No results posted yet for this study

Summary

A clinical study to evaluate the effects on QT/QTc interval of TS-172 in healthy adults subjects

Conditions

  • Healthy Volunteers

Interventions

DRUG

TS-172 20 mg

oral administration of TS-172 20 mg

DRUG

TS-172 90 mg

oral administration of TS-172 90 mg

DRUG

Moxifloxacin

oral administration of moxifloxacin 400 mg

DRUG

Placebo

oral administration of placebo

Sponsors & Collaborators

  • Taisho Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
39 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-03
Primary Completion
2025-05-20
Completion
2025-05-26

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06837155 on ClinicalTrials.gov